Citations

Clear

415 citation(s) found for "Snyder, M".

Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39)
Deal, Allison M. , Sampathkumar, Yashasvini , Ginos, Brenda, Schrag, Deborah , Jansen, Jennifer , Stover, Angela M. , Carr, Philip M., Spears, Patricia A. , Jönsson, Mattias , Thanarajasingam, Gita , Rogak, Lauren , Cella, D, Given, Barbara, Zylla, Dylan M. , Weiss, Anna, Wolf, Anna P., Basch, Ethan , Blinder, V. S., Ginos, Brenda F, Mazza, Gina L , Schrag, Deborah , Jansen, Jennifer , Stover, Angela M , Spears, Patricia A , Jonsson, Mattias , Bennett, Antonia V , Thanarajasingam, Gita , Rogak, Lauren J , Reeve, Bryce B. , Snyder, Claire , Cella, David , Given, Barbara , Zylla, Dylan , Dueck, A. C. , Basch, Ethan , Blinder, Victoria S , Carr, Philip, Geoghegan, Cindy , Given, Barbara , Blinder, Victoria

Mayo Clinic

JCO Oncology Practice | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-26-00015 | PMID 42119041 Get It

PURPOSE Remote symptom monitoring using patient-reported outcomes (PROs) has been shown to improve symptom control and physical function among patients with advanced cancer. However, it is unclear whether these benefits are similar across demographic groups. This exploratory analysis of the PRO-TECT trial examined whether the effects of electronic symptom monitoring varied by race, age, sex, and educational attainment. METHODS PRO-TECT was a cluster randomized trial conducted across 52 US community oncology practices comparing weekly electronic symptom monitoring with usual care (UC). Adult patients with metastatic solid tumors receiving systemic therapy were enrolled (N = 1,191). Participants in the PRO arm completed weekly symptom surveys including the PRO-CTCAE, triggering alerts to the care team for severe or worsening symptoms. Patients chose whether to complete weekly PROs online or via telephone-based interactive voice response not requiring Internet access. Outcomes were measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 symptom control and physical function scales. Subgroup analyses were performed by race (Black v White), age (<65 v ≥65 years), sex (male v female), and educational attainment (≤high school v >high school). RESULTS From baseline to 3 months, PRO participants showed greater improvements in symptom control (+2.37 v −0.20, P = .002) and physical function (+1.54 v −0.93, P = .02) versus UC. Benefits were most pronounced among younger, female, Black, and less educated participants. Black participants in the PRO arm were more likely to report that symptom reporting made them feel more in control of their care compared with White participants. CONCLUSION Electronic symptom monitoring improved quality-of-life outcomes overall, including among groups who have historically experienced higher symptom burden or barriers to communication. Remote PRO systems may represent an equitable strategy to enhance cancer care delivery.
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention
Harrison, Theresa M., Harvey, Danielle J., Chadwick, Trevor, Chao, Yishu , Taggett, Jacinda , Maillard, Pauline, Lovato, Laura, Farias, Sarah, Papp, Kathryn V., Lockhart, Samuel N., Toga, Arthur W., Koeppe, Robert A., Jagust, William J., Whitmer, Rachel A., Snyder, Heather M. , Carrillo, Maria C., Baker, Laura D. , Espeland, Mark A., Vemuri, Prashanthi, DeCarli, Charles, Landau, Susan M., Harvey, Danielle , Carrillo, María C. , Harvey, Danielle J , Harrison, Theresa M. , Maillard, Pauline , Lovato, Laura, Farias, Sarah Tomaszewski , Papp, Kathryn V. , Lockhart, Samuel N. , Toga, Arthur W. , Koeppe, Robert A. , Jung, Youngkyoo , Jagust, William J. , Whitmer, Rachel A. , Espeland, Mark Andrew , Vemuri, Prashanthi , DeCarli, Charles , Landau, Susan

Mayo Clinic

JAMA Neurology | April 20, 2026 | Volume: 83 | Issue: 6 | Pages: 521

10.1001/jamaneurol.2026.0832 | PMID 42008251 Get It

Importance Brain imaging biomarkers may (1) identify underlying mechanisms of intervention effects and (2) define brain characteristics of those most likely to benefit cognitively from the intervention. Objective To test whether (1) a lifestyle intervention is related to brain changes, (2) brain changes are correlated with intervention-specific cognition changes, and (3) brain imaging biomarkers provide information about who is likely to benefit from a lifestyle intervention. Design, Setting, and Participants In this randomized clinical trial, the POINTER Imaging study was an ancillary study of the 2-year, single-blind multicenter US POINTER clinical trial in which neuroimaging data were collected on eligible enrolled participants. The study was conducted from May 2019 to March 2023 (final follow-up, May 14, 2025). Participants were enrolled into the POINTER Imaging study following a standard procedure at 5 clinical sites in the US. Participant eligibility criteria included an age of 60 to 79 years, sedentary lifestyle, and suboptimal diet, plus at least 2 additional risk criteria for cognitive decline and no contraindications for neuroimaging. Interventions Participants were randomly assigned to receive the structured or self-guided intervention. Both interventions emphasized increased physical and cognitive activity, healthy nutrition, social engagement, and cardiovascular health monitoring, but they differed in intensity and accountability. Main Outcomes and Measures There were 4 primary imaging outcomes: global β-amyloid (Aβ) burden, tau burden in the entorhinal cortex (ERC), hippocampal (HC) volume, and white matter hyperintensity volume. The primary cognitive measure was a global cognitive composite. Results Among 1943 parent trial participants who were assessed for eligibility, 983 underwent at least 1 magnetic resonance imaging or positron emission tomography scanning session. The mean (SD) age was 68.4 (5.2) years; 605 participants (61.5%) were female and 378 male (38.5%). Five hundred sixteen participants received the structured intervention and 467 the self-guided intervention. There were no intervention group differences in longitudinal cognitive or imaging outcomes. Intervention group differences were not associated with or moderated by Aβ status or accumulation. There was a negative association between change in ERC tau and change in global cognition in the self-guided group that was attenuated in the structured group (difference in association: 0.289; 95% CI, 0.029 to 0.550; interaction P = .03). Lower baseline HC volume was associated with greater cognitive benefit for participants in the structured group vs the self-guided group (lower HC: 0.077 SD; 95% CI, 0.022 to 0.132; higher HC: 0.002 SD; 95% CI, −0.037 to 0.041; interaction P = .03). Conclusion and Relevance This study found that a high-intensity multidomain lifestyle intervention did not affect brain biomarker trajectories and was not associated with Aβ pathology, but older adults with specific at-risk brain characteristics, including lower baseline HC volume, showed a greater cognitive benefit of the structured intervention. Trial Registration ClinicalTrials.gov Identifier: NCT03688126
The landscape of dementia research, diagnosis, treatment, and care in Latin America
Suemoto, Claudia K., Custodio, Nilton, Avila‐Funes, José A., Baez, Sandra, Bagnati, Pablo , Barnes, Lisa Laverne, D., Brucki Sonia M., Calandri, Ismael L., Cornejo‐Olivas, Mario, Derio, Carolina Delgado, García, Adolfo M., Grinberg, Lea T., Ibanez, Agustin M., Isasi, Rosario, Josephy‐Hernandez, Sylvia , Porras, Maria Lazo, Llibre‐Guerra, Jorge J., Llibre‐Rodriguez, Juan J., Meza, B. Marcela Mar, Migeot, Joaquin, Miranda, J. Jaime, Miranda‐Castillo, Claudia, Mummery, Catherine J., Parodi, José F., Castro, Natalia Pozo, Contreras, Rosa María Salinas, Slachevsky, Andrea, Souza‐Talarico, Juliana Nery, Takada, Leonel T., Tsoy, Elena, Pilalumbo, Martha Unaucho, Zimmer, Eduardo R., Fontana, Igor C. , Snyder, Heather M. , Carrillo, Marı́a C., Carrillo, María C. , Takada, Leonel Tadao , Custodio, Nilton , Ibáñez, Agustín , Suemoto, Cláudia Kimie , Delgado, Carolina , Mahinrad, Simin , Ibañez, Agustín , Suemoto, Claudia Kimie , Aguilar, Diego, Ávila‐Funes, José Alberto , Báez, Sandra , Barnes, Lisa L. , Brucki, Sônia Maria Dozzi , Caramelli, Paulo , Cornejo-Olivas, Mario , Ferreira, Sérgio T. , García, A.R. , Grinberg, Lea T. , Llibre‐Guerra, Jorge J. , Rodríguez, Juan J. Llibre , Lourenco, Mychael V. , Migeot, Joaquín , Miranda, J. Jaime , Miranda‐Castillo, Claudia , Mummery, Catherine J. , Parodi, Jose Francisco , Salinas‐Contreras, Rosa Maria, Santamaría‐García, Hernando A , Slachevsky, Andrea , Souza‐Talarico, Juliana Nery , Surace, Ezequiel , Tsoy, Elena , Unaucho‐Pilalumbo, Martha , Zimmer, Eduardo Rigon , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia | March 27, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71309 | PMID 41894159 Get It

Abstract Latin America is undergoing rapid population aging alongside a rising burden of dementia. While the region holds substantial potential for dementia risk reduction, challenges remain, such as delayed diagnoses, limited access to specialized care and biomarker testing, persistent stigma, and deep‐rooted structural inequities. To address these gaps and foster regionally informed solutions, the Alzheimer's Association convened the 2025 Alzheimer's Association International Conference (AAIC) Satellite Symposium in Lima, Peru, on May 14–15, in collaboration with the Global Brain Health Institute (GBHI) and the Atlantic Fellows for Equity in Brain Health. The meeting aimed to bring core elements of the global AAIC meeting to regional Latin American settings, recognizing that national and cultural contexts demand tailored approaches to dementia prevention, risk reduction, treatment and care all aimed at promoting brain health in the region. This manuscript synthesizes the symposium's key discussions, scientific advances, and opportunities for collaboration across the region.
Current Practices in Social Determinants of Health Screening in Commission on Cancer Hospitals
Francescatti, Amanda B. , Cotler, Joseph H. , Pastore, Bell M, Mullett, Timothy W. , Hedlund, Susan , Kirstein, Laurie , Snyder, Rebecca A, Chan, Kelley , Pastore, B, Boughey, Judy C. , Snyder, Rebecca

Mayo Clinic

Journal of the American College of Surgeons | March 23, 2026 | Volume: 243 | Issue: 3 | Pages: 670-680

10.1097/xcs.0000000000001933 | PMID 41869951 Get It

BACKGROUND: Social determinants of health (SDOH) are associated with adverse cancer outcomes, yet the prevalence and impact of SDOH screening across Commission on Cancer (CoC)-accredited programs are unknown. We evaluated national SDOH screening practices and their association with adherence to CoC quality measures. STUDY DESIGN: A cross-sectional survey of 1,445 CoC-accredited programs (October to December 2024) was linked to National Cancer Database data (2020 to 2022). Adult patients treated at 435 responding hospitals (30.1%) were included. Programs were categorized by routine outpatient SDOH screening status. Multivariable logistic regression assessed associations between screening and receipt of quality measure–concordant care, adjusting for screening duration, age, race, ethnicity, Charlson Comorbidity Index, insurance status, rurality, and program type or case count. RESULTS: Of 435 programs, 165 (37.9%) reported routine SDOH screening. Screening programs more frequently treated ≥10% Medicaid or uninsured patients (29.1% vs 19.6%, p = 0.023). Mean performance was higher at screening hospitals for breast radiation within 60 days (66.6% vs 64.6%, p = 0.046), colon adjuvant chemotherapy within 120 days (84.6% vs 81.9%, p = 0.018), and lung systemic therapy within 90 days (77.2% vs 75.4%, p = 0.043). On adjusted analysis, screening for more than 3 years was independently associated with timely colon adjuvant chemotherapy (odds ratio 1.05; 95% CI 1.01 to 1.07; p = 0.033). Findings persisted after excluding safety net hospitals. CONCLUSIONS: Only one-third of responding CoC programs routinely screen for SDOH. Sustained screening was independently associated with improved adherence to time-sensitive colon cancer chemotherapy, supporting integration of patient-level SDOH assessment into oncology care delivery.
Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Paolillo, Emily W., Wise, Amy, Kaye, Jeffrey A., Beattie, Zachary , Dhanam, Sreya, Casaletto, Kaitlin B. , Saloner, Rowan, Mendez, Mario F., Vandevrede, Lawren, Ljubenkov, Peter A. , Seeley, William W., Gorno-Tempini, Maria Luisa, Miller, Bruce L., Heuer, Hilary W. , Forsberg, Leah K., Kornak, John , Boeve, Bradley F., Boxer, Adam L., Rosen, Howard J., Walsh, Christine M., Staffaroni, Adam M., Abdullah, Muhammad, Apostolova, Liana , Ece, Bayram, Botha, Hugo, Brushaber, Danielle , Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S., Dickerson, Bradford, Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily , Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana M., Galasko, Douglas R., Gavrilova, Ralitza, Gendron, Tania, Geschwind, Daniel, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Grossman, Murray, Hales, Chadwick M., Hall, Matthew, Honig, Lawrence S., Hsiung, Ging-Yuek (Robin), Huang, Eric S., Huey, Edward D, Irwin, David, Johnson, Noah, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler, Kwan, Justin Y., Lago, Argentina Lario , Lapid, Maria, Lavigne, Shannon B., Lee, Suzee, Litvan, Irene, Lucente, Diane , Mackenzie, Ian R., Masdeu, Joseph C. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pascual, Belen, Paulson, Henry, Petrucelli, Leonard, Pressman, Peter, Rademakers, Rosa, Ramanan, Vijay, Ramos, Eliana Marisa , Rankin, Katherine P., Rao, Meghana, Rascovsky, Katya, Rhoads, Kristoffer , Ritter, Aaron, Rogalski, Emily, Rojas, Julio C., Savica, Rodolfo, Snyder, Allison, Sullivan, Anna Campbell, Syrjanen, Jeremy, Tartaglia, M. Carmela, Taylor, Jack, Weintraub, Sandra, Wint, Dylan , Wong, Bonnie, Yokoyama, Jennifer, Mendez, Mario F. , VandeVrede, Lawren , Paolillo, Emily W. , Wise, Amy B. , Saloner, Rowan , Forsberg, Leah Kathleen, VandeVrede, Lawren , Mendez, Mario , Paolillo, Emily W , Kaye, Jeffrey , Au-Yeung, Wan-Tai Michael , Dhanam, Sreya , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Forsberg, Leah K. , Kremers, Walter K. , Boeve, Bradley F. , Boxer, Adam L. , Rosen, Howard J. , Walsh, Christine M. , Staffaroni, Adam M. , Appleby, Brian S. , Barmada, Sami , Bozoki, Andrea C , Domoto‐Reilly, Kimiko , Galasko, Douglas , Gavrilova, Ralitza H. , Gendron, Tania F. , Geschwind, Daniel H., Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grossman, Murray, Hales, Chadwick M. , Hall, Matthew , Honig, Lawrence, Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Knopman, David, Kwan, Justin , Lavigne, Shannon B., Léger, Gabriel C. , Litvan, Irene , Mackenzie, Ian R. , Masdeu, Joseph C , McMillan, Corey T. , Mester, Carly , Molden, Joie, Pantelyat, Alexander , Pascual, Belén , Petrucelli, Leonard , Pressman, Peter , Rademakers, Rosa, Rankin, Katherine P. , Rao, Meghana , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Rojas, Julio C. , Savica, Rodolfo , Snyder, Allison , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Taylor, Jack C. , Tipton, Philip W. , Vandebergh, Marijne , Weıntraub, Sandra , Wong, Bonnie

Mayo Clinic

Neurology Open Access | February 18, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1212/wn9.0000000000000068 | PMID 41987885 Get It

Incorporating Pelvic Floor Physical Therapy in the Treatment of Obstructed Defecation Syndrome and Posterior Compartment Pelvic Organ and Rectal Prolapse: Proceedings of the Consensus Meeting of the Pelvic Floor Consortium of the American Society of Colon
Traugott, Amber , Barten, Julia, Bordeianou, Liliana , Carboni, Cristiane , Carver, Donna, Cucchiara, Meghan Markowski, Gallo, Gaetano, Grimes, Cara L. , Knoepp, Leise R., McClure, Amanda M., Mellgren, Anders, Olson, Craig , Paquette, Ian M., Perry, William R., Snyder, Allison D., Spivak, A, Wells, Katerina O. K., Weinstein, Milena M. , Gurland, Brooke , Perry, William , Traugott, Amber L , Perry, William R , Gallo, Gaetano , Spivak, Anna R.

Mayo Clinic

Diseases of the Colon & Rectum | February 12, 2026 | Volume: 69 | Issue: 3 | Pages: 346-359

10.1097/dcr.0000000000003993 | PMID 41677229 Get It

BACKGROUND: Obstructed defecation syndrome and posterior compartment (rectal) prolapse significantly impact patients’ quality of life. Pelvic floor physical therapy is a critical part of multidisciplinary management for these conditions, yet there is little guidance or standardization to guide providers’ referral practices, diagnostic approaches, or treatment. OBJECTIVE: To develop multidisciplinary consensus-based recommendations for incorporating pelvic floor physical therapy into the treatment of obstructed defecation syndrome and posterior compartment prolapse. DATA SOURCES: MEDLINE, PubMed, Embase, and the Cochrane Database of Systematic Reviews were searched for English-language studies on pelvic floor physical therapy, obstructed defecation, diagnostic criteria, imaging, and pelvic organ prolapse. STUDY SELECTION: Studies identified in the literature search were reviewed by multidisciplinary expert subgroups, who formulated draft statements based on the available evidence. INTERVENTION: Consensus meetings were conducted and included experts from colorectal surgery, urogynecology, physical therapy, gastroenterology, radiology, and urology. Statements were evaluated via structured discussions and voting processes. Those reaching more than 70% consensus were adopted for inclusion. Statements underwent final review and editing by the leadership of the American Society of Colon and Rectal Surgeons and the International Urogynecological Association. MAIN OUTCOME MEASURES: Consensus statements addressed referral criteria, diagnostic evaluations, therapy protocols, timing, coordination with surgery, and management of anatomical abnormalities. RESULTS: Fifteen statements reached consensus. Key recommendations included prompt referral to pelvic floor physical therapy for patients without contraindications, individualized therapy based on appropriate diagnostic evaluation and patient goals, timing of pelvic floor physical therapy relative to surgery, and trauma-informed patient care. LIMITATIONS: Recommendations primarily reflect expert consensus due to limited high-quality evidence. Variability in practitioner expertise and geographic access to trained therapists are barriers to consistent implementation. CONCLUSIONS: These recommendations provide structured guidance for integrating pelvic floor physical therapy into the management of obstructed defecation syndrome and rectal prolapse. Additional research and standardized training are essential to optimize patient outcomes.
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling
Dutt, Shubir , Leichter, Dana, Wolf, Amy , Kornak, John , Clark, Annie L , Russell, Lucy L. , Bouzigues, Arabella , Cash, David M, Bocchetta, Martina , Olzinski, Molly, Ece, Bayram, Borroni, Barbara, Butler, Chris R., Clark, David, Convery, Rhian S., Darby, R. Ryan , Mendonça, Alexandre de, Dickerson, Bradford, Domoto‐Reilly, Kimiko, Ducharme, Simon, Ferry‐Bolder, Eve, Finger, Elizabeth, Foster, Phoebe H. , Galasko, Douglas R., Galimberti, Daniela, Gerhard, Alexander, Ghoshal, Nupur , Graff, Caroline, Graff‐Radford, Neill, Grant, Ian M., Hales, Chadwick M., Honig, Lawrence S., Hsiung, Ging‐Yuek, Huey, Edward D, Irwin, David John, Jiskoot, Lize C., Kremers, Walter K. , Kwan, Justin Y., Laforce, Robert, Ber, Isabelle Le, Levin, J, Litvan, Irene, Mackenzie, Ian R., Masellis, Mario, Mendez, Mario F., Moreno, Fermin, Onyike, Chiadi U. , Otto, M, Pascual, Belen, Pressman, Peter , Rademakers, Rosa, Ramos, Eliana Marisa , Ritter, Aaron, Roberson, Erik D. , Sánchez‐Valle, Raquel, Santana, Isabel, Seelaar, Harro, Snyder, Allison, Sorbi, Sandro, Synofzik, Matthis, Tartaglia, Maria Carmela, Swieten, John C. van, Vandebergh, Marijne , Vandenberghe, Rik, Heuer, Hilary W. , Miller, Bruce L., Seeley, William W., Gorno‐Tempini, Maria Luisa, Kramer, Joel H., Forsberg, Leah K., Kantarci, Kejal, Boeve, Bradley F., Boxer, Adam L. , Rohrer, J. D., Rosen, Howard J., Staffaroni, Adam M., investigators, FTD Prevention Initiative (FPI), Graff, Caroline , Galimberti, Daniela , Otto, Markus , Jiskoot, Lize C. , Moreno, Fermín , Domoto‐Reilly, Kimiko , Russell, Lucy L , Bocchetta, Martina , Bayram, Ece , Ducharme, Simon , Finger, Elizabeth C. , Galimberti, Daniela , Ghoshal, Nupur , Irwin, David J , Kwan, Justin Y , Le Ber, Isabelle , Otto, Markus , Pascual, Belen , Snyder, Allison , Synofzik, Matthis , Tartaglia, Maria Carmela , Tiraboschi, Pietro , Kantarci, Kejal , Rohrer, Jonathan D , Roberson, Erik , Kremers, Walter K , Domoto-Reilly, Kimiko , Vandebergh, Marijne , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Cobigo, Yann , Cash, David M. , Appleby, Brian S. , Borroni, Barbara , Bozoki, Andrea C , Clark, David, Convery, Rhian , Mendonça, Alexandre de , Ducharme, Simon , Ferry‐Bolder, Eve , Galasko, Douglas , Gerhard, Alexander , Graff‐Radford, Neill R. , Hales, Chadwick M. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kwan, Justin , Laforce, Robert , Ber, Isabelle Le , Léger, Gabriel C. , Xiong, Chengjie , Litvan, Irene , Mackenzie, Ian R. , Masellis, Mario , Mendez, Mario F. , Pascual, Belén , Rademakers, Rosa , Rowe, James B. , Sánchez‐Valle, Raquel , Santana, Isabel , Seelaar, Harro , Snyder, Allison , Sorbi, Sandro , Synofzik, Matthis , Tiraboschi, Pietro , Swieten, John C. van , Vandenberghe, Rik , Seeley, William W. , Gorno‐Tempini, Maria‐Luisa, Kramer, Joel H. , Forsberg, Leah K. , Kantarci, Kejal , Boeve, Bradley F. , Rohrer, Jonathan D. , Rosen, Howard J. , Staffaroni, Adam M.

Mayo Clinic

Annals of Neurology | January 29, 2026 | Volume: 99 | Issue: 5 | Pages: 1315-1326

10.1002/ana.78167 | PMID 41608854 Get It

Objective Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD. We used a Bayesian linear mixed‐effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods Participants included 234 asymptomatic or prodromal carriers of C9orf72 , GRN , or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1‐weighted scans. The BLME models established individual voxel‐wise gray matter trajectories using the first 2 scans. Person‐specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time‐varying Cox proportional hazard models covarying for age. Receiver‐operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results The BLME cluster volume predicted conversion to dementia in f‐FTLD mutation carriers overall and separately in C9orf72 , GRN , and MAPT , with comparable hazard ratios observed for atrophy W‐maps and regional volumes. Within a 24‐month timeframe, BLME cluster volume discriminated dementia converters from non‐converters with larger areas under the curve (AUCs) than other approaches. Interpretation Bayesian‐modeled individualized atrophy scores predict dementia progression among asymptomatic f‐FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a
Abstract DP020: Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage The QUANTUM Randomized Clinical Trial
Ironside, Natasha , Patrie, James, Kumar, Jeyan S. , Naamani, Kareem El, Abbas, Rawad , Becerril, Andrea Pecina, Chen, Ching-Jen, Rizvi, Tanvir , Mastorakos, Panagiotis , Naamani, Kareem El , Snyder, M. Harrison

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp020 Get It

Introduction: Optimizing patient selection and time-to-intervention will be crucial to the success of future clinical trials seeking to implement therapies and improve intracerebral hemorrhage (ICH) patient outcomes. Automated and accurate ICH and perihematomal edema (PHE) volumetry carries significant potential to strengthen trials targeting ICH and PHE expansion. Aims: The Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage (QUANTUM) trial was designed with aims of (1) validating a fully automated artificial intelligence (AI) method for supratentorial, spontaneous ICH and PHE volumetry against the manual and semiautomated quantification methods and (2) establishing a model framework for the translation of AI technology through conduct of a clinical trial under the equivalence hypothesis paradigm. Methods: This trial was a prospective, randomized, clinical study with blinded outcome assessment. Six independent raters were randomized in a 1:1 ratio to ICH and PHE volumetry from non-contrast CT scans in the Virtual International Stroke Trials Archive with either the semiautomated or manual quantification method. The primary outcomes were equivalence between (1)ICH volume measurements on admission (<24h from symptom onset) for the manual versus the fully automated or the sem-automated quantification methods, and (2)PHE volume measurements on day 3 (72±12h from symptom onset) for the manual versus the fully automated or the semiautomated quantification methods. The required sample size was 126 ICH and 126 PHE measurements, based upon a significance level of 0.025 to account for the two equivalence tests. Results: The geometric mean relative discrepancies between the fully automated and the manual ICH and PHE volume measurements did not cross the pre-specified 10% equivalence margin. The geometric mean relative discrepancies between the semiautomated and the manual ICH and PHE volume measurements did cross the pre-specified 10% equivalence margin. The fully automated method (mean 10.0±2.7s/scan) was significantly faster than the manual (mean 189±199 s/scan; P <0.001) and semiautomated (mean 79±68s/scan; P <0.001) methods. Conclusions: ICH and PHE volumes quantified by AI could replace clinician measurements within a 10% error margin and with substantially greater efficiency. The semiautomated method could not replace manual measurements. This trial demonstrated feasibility of the equivalence hypothesis framework for AI validation studies.
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR
Alger, Emily , Aiyegbusi, Olalekan Lee , Dueck, A. C. , Minchom, Anna, pe, madeline, Peipert, John Devin , Snyder, C. J., Symeonides, Stefan N. , Wilson, Roger , Basch, Ethan , Qiao, Yu , Dean, Lizzie, Hansen, Aaron R. , Kholmanskikh, Olga , Kobayashi, Ken, Tourneau, Christophe Le, Lee, J. Jack, Patel, Sheetal, Petrie, Joan, Pond, Gregory R. , Prior, Kieran, Rantell, Khadija , Reeve, John F., Solovyeva, O., Wages, Nolan A. , Weber, Harald A., Yap, C., Dueck, Amylou C. , Yap, Christina , Snyder, Claire , Minchom, Anna , Snyder, Claire , Bates, Susan E , Bulbeck, Helen , Di Maio, Massimo , Hansen, Aaron R , Kholmanskikh, Olga , Kobayashi, Ken , Landers, Dónal , Lee, J Jack , Ma, Brigette B Y , Marshall, Lynley V , Petrie, Joan , Pond, Gregory Russell , Solovyeva, Olga , Wages, Nolan A , Yap, Christina , Peipert, John Devin , Pe, Madeline , Basch, Ethan , Bates, Susan E. , Bulbeck, Helen , Tourneau, Christophe Le , Ma, Brigette , Weber, Harald, Calvert, Melanie

Mayo Clinic

Journal of Clinical Oncology | January 23, 2026 | Volume: 44 | Issue: 8 | Pages: 709-719

10.1200/jco-25-01625 | PMID 41576310 Get It

PURPOSE There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual consensus meeting (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation—ultimately contributing to the development of safer, more effective therapies.
Research Code Sharing in Support of Gold Standard Science
Klonoff, David C., Espinoza, Juan, Mader, Julia K., Heinemann, Lutz, Cobelli, Claudio, Kerr, David , Kovatchev, Boris, Najafi, Bijan , Prahalad, Priya , Zheng, Yaguang , Shao, Mandy M. , Scheideman, Agatha F. , DuNova, Ashley Y. , Kohn, Michael , Umpierrez, Guillermo E., Malek, Aiman Abdel, Agus, Michael S. D., Ahn, David T., AlSaad, Rawan , AL-SOFIANI, MOHAMMED, Armstrong, David, Arnold, Mark A., Bequette, B. Wayne , Bellazzi, Riccardo, Cengiz, Eda, Chase, J. Geoffrey, Chen, Jake Y. , Cichosz, Simon Lebech , Clements, Mark A. , Close, Kelly L., Cuadros, Jorge , Contreras, Ivan, Drincic, Andjela , Facchinetti, Andrea, Fleming, G. Alexander , Gabbay, Monica A. L., Healey, Elizabeth, Hoang, Thanh D., Kulzer, Bernhard, Belle, Jeff La, Lee, Aaron, Lee, Cecilia S., Lee, Wei-An , Liepmann, Dorian , Maahs, David M. , Mathioudakis, Nestoras, Metwally, Ahmed A., Mohan, Viswanathan, Moon, Sun-Joon, Raeder, Helge, Rhee, Connie, Rhee, Eun-Jung, Scheinker, David , Shah, Viral N., Snyder, Michael P., Sode, Koji, Spanakis, Elias K., Svensson, Jannet, Vaswani, Nitin, Vareth, Maryam, Wallia, Amisha , Wang, Tao, Williams, Ebonie, Wolf, Ruth, Wong, Jenise C., Yeshiwas, Sewagegn, Shah, Shahid N. , Cobelli, Claudio , Snyder, M , Kovatchev, Boris , Heinemann, Lutz , Espinoza, Juan , Mathioudakis, Nestoras , Mader, Julia K. , Klonoff, David C , Espinoza, Juan , Mader, Julia K , Heinemann, Lutz , Cobelli, Claudio , Kovatchev, Boris , Umpierrez, Guillermo E. , Wong, Tien Y , Abdel Malek, Aiman , Agus, Michael S D , Ahn, David T , AlSaad, Rawan , Al-Sofiani, Mohammed E , Armstrong, David , Arnold, Mark A , Bee, Yong Mong , Bequette, B Wayne , Bellazzi, Riccardo , Cengiz, Eda , Chase, James Geoffrey , Chen, Haipeng , Chen, Jake Y , Cichosz, Simon L , Cinar, Ali , Clements, Mark A , Close, Kelly L , Cuadros, Jorge , Contreras, Ivan , Datta, Gora , Dhatariya, Ketan , Doyle, Francis J , Drincic, Angela , Facchinetti, Andrea , Fleming, G Alexander , Foreman, Joshua , Gabbay, Monica A L , Gutierrez-Osuna, Ricardo , Healey, Elizabeth , Hoang, Thanh D , Jacobs, Peter G , Kulzer, Bernhard , La Belle, Jeff , Lee, Aaron Y , Lee, Cecilia S , Lee, Wei-An Andy , Liepmann, Dorian , Maahs, David M , Mathioudakis, Nestoras N , Meo, Sultan A , Metwally, Ahmed A , Misra, Shivani , Mohan, Viswanathan , Moon, Sun-Joon , Raeder, Helge , Rhee, Connie M , Rhee, Eun-Jung , Scheinker, David , Shah, Viral N , Sheng, Bin , Snyder, Michael , Sode, Koji , Spanakis, Elias K , Svensson, Jannet , Vaswani, Nitin , Vareth, Maryam , Vehi, Josep , Wallia, Amisha , Waki, Kayo , Wang, Tao , Williams, Eric , Wolf, Risa M , Wong, Jenise C , Bekele, Sewagegn Yeshiwas , Zilbermint, Mihail , Shah, Shahid N , Klonoff, David C. , DuBord, Ashley Y., Wong, Tien Yin , Agus, Michael S. D. , Ahn, David , Close, Kelly L. , Dhatariya, Ketan , Doyle, Francis J. , Rhee, Connie M. , Sode, Koji , Spanakis, Elias K. , Waki, Kayo , Wong, Jenise C. , Zilbermint, Mihail

Mayo Clinic

Journal of Diabetes Science and Technology | January 14, 2026 | Volume: 20 | Issue: 3 | Pages: 609-619

10.1177/19322968251391819 | PMID 41532590 Get It

Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.